NASDAQ:TLGT

Teligent - TLGT Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Compare

Today's Range: N/A
50-Day Range: $0.01
▼
$0.05
52-Week Range: N/A

Volume: 6,460 shs
Average Volume: N/A
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Teligent (NASDAQ:TLGT) Stock

Teligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.

Receive TLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teligent and its competitors with MarketBeat's FREE daily newsletter.

TLGT Stock News Headlines

July 18, 2022 | finance.yahoo.com

Lidocaine Market Size is projected to reach USD 3.05 Billion by 2029, growing at a CAGR of 8.45%: Straits Research - Yahoo Finance

May 3, 2022 | finance.yahoo.com

Topical Drugs Market Size to Grow by USD 70.95 billion from 2021 to 2026 | Driven by Increase in the Prevalence of Skin Diseases | Technavio - Yahoo Finance

April 1, 2022 | wsj.com

Alex Mandl, Who Gave Up a Top AT&T Job to Lead a Startup, Has Died at Age 78 - The Wall Street Journal

February 28, 2022 | bizjournals.com

Teligent seeks to convert bankruptcy to Chapter 7 amid impasse with creditors - Philadelphia Business Journal - Philadelphia Business Journal

February 3, 2022 | morningstar.co.uk

Hikma completes acquisition of Teligent's Canadian... - Morningstar

January 17, 2022 | marketwatch.com

Hikma to Buy Canadian Assets of Teligent for $45.75 Mln - MarketWatch

January 17, 2022 | lse.co.uk

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million | Financial News - London South East

December 8, 2021 | nasdaq.com

FDA Approves Daré Bioscience's Xaciato For Bacterial Vaginosis - Nasdaq

December 8, 2021 | finance.yahoo.com

Rocket Pharmaceuticals Appoints Martin L. Wilson as General Counsel and Chief Compliance Officer - Yahoo Finance

December 2, 2021 | marketwatch.com

Atropine Sulfate Market Analysis By Industry Size, Share, Revenue Growth, Development And Demand Forecast To 2028

November 11, 2021 | wsj.com

Plaintiffs Want Teligent Price-Fixing Lawsuit to Continue Despite Bankruptcy - The Wall Street Journal

November 10, 2021 | wsj.com

Firm Retention Summary: Teligent Inc.

October 27, 2021 | globenewswire.com

Delisting of Securities of Teligent, Inc. from The Nasdaq Stock Market - GlobeNewswire

October 20, 2021 | wsj.com

Firm Retention Summary: Teligent Inc. - The Wall Street Journal

October 15, 2021 | reuters.com

Generic drugmaker Teligent approved to tap bankruptcy loan - Reuters

October 15, 2021 | bloomberg.com

Generic Drug Maker Teligent Files Bankruptcy, Plans Sale - Bloomberg

October 15, 2021 | nasdaq.com

Teligent Files For Chapter 11 Bankruptcy

October 14, 2021 | marketwatch.com

Teligent Files for Bankruptcy, to Pursue Asset Sale - MarketWatch

October 14, 2021 | finance.yahoo.com

Generic drug maker Teligent files for bankruptcy protection, explores sale of the company

October 14, 2021 | finance.yahoo.com

Teligent to Pursue Asset Sale through Voluntary Chapter 11 Process

October 5, 2021 | finance.yahoo.com

Journey Medical Corporation Appoints Ernest De Paolantonio as Chief Financial Officer - Yahoo Finance

September 30, 2021 | seekingalpha.com

TLGT stock rebounds after resignations of senior executives (NASDAQ:TLGT) - Seeking Alpha

August 30, 2021 | benzinga.com

Teligent Pharma Issued Voluntary Recall Of Lidocaine Topical Solution 4%, Cites 'Super Potency' - Benzinga

August 30, 2021 | benzinga.com

FDA Says Teligent Pharma Has Not Received Any Reports Of Adverse Events Related To Co. Recall - Benzinga

August 19, 2021 | businesswire.com

Scott+Scott Attorneys at Law LLP Announces a Notice of Proposed Settlement of Class Action for the Teligent, Inc. Securities Class Action - Business Wire

See More Headlines

Receive TLGT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teligent and its competitors with MarketBeat's FREE daily newsletter.

TLGT Company Calendar

Last Earnings: 8/16/2021
Today: 8/12/2022
Next Earnings (Estimated): 8/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:TLGT
CUSIP: N/A
CIK: 352998
Web: www.teligent.com
Phone: (856) 697-1441
Fax: 856-697-1442
Employees: 2,357
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $45.31 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($5.06) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 92,820,000
Free Float: 92,659,000
Market Cap: N/A
Optionable: Optionable
Beta: N/A

Key Executives

Timothy B. Sawyer
President, Chief Executive Officer & Director
Antonio di Nicola
Vice President-Operations & General Manager
Alyssa Lozynski
Chief Financial Officer
Devendra Shah
Vice President-Research & Development
Philip K. Yachmetz
Secretary, Chief Legal Officer & Executive VP

Key Competitors

View All Competitors

TLGT Stock - Frequently Asked Questions

When is Teligent's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our TLGT earnings forecast.
How were Teligent's earnings last quarter?: Teligent, Inc. (NASDAQ:TLGT) released its earnings results on Monday, August, 16th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.01. The business earned $10.43 million during the quarter.
When did Teligent's stock split?: Shares of Teligent reverse split before market open on Thursday, May 28th 2020. The 1-10 reverse split was announced on Wednesday, May 27th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 27th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Tim Sawyer's approval rating as Teligent's CEO?: 2 employees have rated Teligent Chief Executive Officer Tim Sawyer on Glassdoor.com. Tim Sawyer has an approval rating of 100% among the company's employees. This puts Tim Sawyer in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Teligent own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Teligent investors own include Novavax (NVAX), ChemoCentryx (CCXI), Voyager Therapeutics (VYGR), AbbVie (ABBV), General Electric (GE), Biocept (BIOC), Lannett (LCI), Pfizer (PFE), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).
What is Teligent's stock symbol?: Teligent trades on the NASDAQ under the ticker symbol "TLGT."
How much money does Teligent make?: Teligent (NASDAQ:TLGT) has a market capitalization of $0.00 and generates $45.31 million in revenue each year.
How many employees does Teligent have?: The company employs 2,357 workers across the globe.
How can I contact Teligent?: Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The official website for the company is www.teligent.com. The company can be reached via phone at (856) 697-1441, via email at investorrelations@teligent.com, or via fax at 856-697-1442.

This page (NASDAQ:TLGT) was last updated on 8/12/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources